MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm

CME: 1.0

Target Audience

The target audience for this activity is optometrists and other health care professionals who are involved in the management of patients with MGD-associated DED.

Activity Overview

Meibomian gland dysfunction (MGD) is a complex, multifactorial disorder that can lead to altered tear film composition and ocular surface disease. In fact, MGD is one of the most common causes of dry eye disease (DED). Although multiple treatment options are available, therapies that target the underlying pathophysiology of the disease are lacking. Emerging agents with novel mechanisms for treating MGD may ultimately provide new treatment alternatives.

This Community Practice Connections program provides an in-depth review of some of the key highlights from a live symposium held during the American Academy of Optometry Annual Meeting 2022 in October. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with MGD-associated DED, putting recent clinical trial data into clinical context. The program is designed for clinicians who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:
  • Distinguish burden of disease associated with MGD-associated DED
  • Analyze key trial data surrounding therapies used for the treatment of MGD-associated DED
  • Recognize the mechanisms of action of emerging agents for the treatment of MGD-associated DED
  • Evaluate safety, efficacy, and key clinical trial data for emerging agents being studied for the potential treatment of MGD-associated DED

Post a comment to this article